Novartis AG ADR (NVS)vsVistaGen Therapeutics Inc (VTGN)
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $282.11B
VTGN
VistaGen Therapeutics Inc
$0.61
+2.94%
HEALTHCARE · Cap: $23.64M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 7170749% more annual revenue ($56.58B vs $789,000). NVS leads profitability with a 23.9% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
VTGN
Avoid34
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$147.85
$38.25 premium
Margin of Safety
+71.0%
Fair Value
$1.88
Current Price
$0.61
$1.27 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Reasonable price relative to book value
Revenue surging 29.5% year-over-year
Areas to Watch
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -101.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : VTGN
The strongest argument for VTGN centers on Price/Book, Revenue Growth. Revenue growth of 29.5% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Bear Case : VTGN
The primary concerns for VTGN are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
NVS profiles as a declining stock while VTGN is a growth play — different risk/reward profiles.
NVS carries more volatility with a beta of 0.52 — expect wider price swings.
VTGN is growing revenue faster at 29.5% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 34/100), backed by strong 23.9% margins. VTGN offers better value entry with a 71.0% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →VistaGen Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to developing and commercializing several drugs with the potential to treat anxiety, depression, and other central nervous system (CNS) disorders. The company is headquartered in South San Francisco, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?